^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-A1201 (trastuzumab emtansine biosimilar)

    i
    Other names: SHR-A1201
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Microtubule inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study. (PubMed, Anticancer Drugs)
    The maximum tolerated dose of SHR-A1201 was not lower than that of T-DM1 (3.6 mg/kg). SHR-A1201 was well tolerated and safe in patients with advanced HER2-positive breast cancer. The pharmacokinetics parameters showed a linear trend, and the immunogenicity results met the clinical expectations.
    P1 data • PK/PD data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    |
    Kadcyla (ado-trastuzumab emtansine) • SHR-A1201 (trastuzumab emtansine biosimilar)